Navigation Links
Use of a fast-acting insulin analog to control diabetic ketoacidosis in Children

Diabetic ketoacidosis (DKA) is a life-threatening condition that frequently requires hospitalization in children with type 1 diabetes.// The critical factors in the treatment of DKA include careful and frequent monitoring of the patient, skillful fluid and electrolyte adjustment, and the initiation of insulin therapy after the initial restoration of fluid volume has been achieved. Continuous low-dosage intravenous infusion of soluble insulin has been the procedure of choice for this because it provides direct control and results in a predictable rate of fall in serum glucose levels. However, admission to an intensive care unit to receive intravenous insulin infusion increases health care costs.

A recent study proposes using a subcutaneous fast-acting analog of human insulin instead of intravenous continuous regular insulin to avoid the need for a second intravenous line, simplify treatment of DKA in children, and provide a more economical solution. The aim of the study was to compare the efficacy of a subcutaneous fast-acting analog (lispro) with continuous intravenous regular insulin (CIRI) in the treatment of pediatric DKA.

The fluid replacement protocol aimed at correcting intravascular volume up to the normalization of the peripheral perfusion. Once cardiovascular stability was achieved, the child was alert, and vomiting has stopped, oral rehydration was started. Cerebral edema, the most feared complication of DKA, did not develop in the patients during this study. Also, there were no deaths or "near death" episodes, and no patient had to be treated with mannitol.

The study, published in the August issue of Diabetes Care concludes that DKA treatment with a subcutaneous fast-acting insulin analog represents a cost-effective and technically simplified procedure that precludes intensive care unit admission.


'"/>




Page: 1

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Brain stem cells to help in producing insulin
3. Now insulin can be inhaled
4. Exubera could mean the end of an insulin injection era for diabetics
5. Islet cells producing insulin cultivated in the lab
6. Pfizer vouches safety of long-term inhaled insulin.
7. Uncontrolled blood pressure
8. FDAs control is inherently weak
9. Drugs control and industry departments to share a common e-platform
10. Self control makes stress response easy
11. Progression of Glaucoma could be controlled with early detection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... VA (PRWEB) , ... January 18, 2017 , ... Dr. ... in family, cosmetic and implants dentistry. His modern dental practice has two convenient office ... as a 2017 Top Rated Dentist for the Alexandria area. This award ...
(Date:1/18/2017)... ... 18, 2017 , ... Rollerblade®, the worldwide leader in inline ... braking system that allows skaters of all levels to stop safely with more ... of beginner and intermediate skaters – learning how to brake with more balance ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – ... to choose the best drug option for each patient. Dentists have several general anesthesia ... overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
(Date:1/17/2017)... Grove Village, IL (PRWEB) , ... January 17, ... ... for musicians and music enthusiasts at the National Association of Music Merchants (NAMM) ... January 19 – 22, 2017. , Etymotic’s ER•4® has long been the gold ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, the ... cell and advanced therapies , has announced a ... company developing "tumor starvation" treatments for acute leukemia ... Under the agreement, Invetech will develop systems to ... Erytech,s proprietary ERYCAPS technology platform, which uses a ...
(Date:1/18/2017)... MIAMI , January 18, 2017 ... announced the company plans to publish an online ... the Company,s preliminary sales forecast for 2017. Management ... Company,s trialing ninety-day record sales performance from its ... recently announced entry into the Cannabis sector ...
(Date:1/18/2017)... Authority Chinese Food and Drug Administration CSL ... Institute Food and Drug Administration FORT ... Glaxo Smith Klein GlaxoWellcome Global Influenza ... Immune Targeting Systems Indian Association of ... Johnson & Johnson Krka Pharmaceuticals Medicago ...
Breaking Medicine Technology: